Form 4: Vertex Pharma Exec Sells Shares Under 10b5-1 Plan

Vertex Pharmaceuticals EVP and CMO Carmen Bozic sold 2,329 shares of common stock for $480.31 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc. (VRTX), reported a sale of common stock.
• The transaction involved the disposition of 2,329 shares of common stock.
• The shares were sold at a price of $480.31 per share.
• The transaction occurred on February 27, 2026.
• Following this transaction, Carmen Bozic beneficially owns 37,734 shares of common stock.
• The sale was executed pursuant to a company-approved trading plan under Rule 10b5-1, which was established on November 20, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was pre-planned under a 10b5-1 plan, which typically mitigates any negative signaling associated with insider selling.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common for executives to manage personal finances and diversify holdings, often pre-scheduled to avoid accusations of trading on material non-public information. This is a routine disclosure for a pharmaceutical company executive.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be perceived differently by investors, though the 10b5-1 plan context often neutralizes negative interpretations.

Key Dates

Recommendation

The filing details a routine, pre-scheduled insider stock sale under a 10b5-1 plan. Such transactions are typically for personal financial management and do not reflect a change in the company's fundamental outlook or performance. Therefore, it does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Stock Sale, Carmen Bozic, 10b5-1 Plan